UNSPSC 51313404: Brompheniramine

This classification denotes a histamine-1 receptor antagonist with the molecular formula C16H19BrN2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier H57G17P2FN, chemically known as 3-(p-bromophenyl)-3-(2-pyridyl)-n,n-dimethylpropylamine but generally known as brompheniramine, which bears US NIH Compound Identifier 6834. Brompheniramine most often comes in base and maleate forms. European Medicines Agency schedules Brompheniramine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05924MIG.

UNSPSC 51313404 Brompheniramine is a Commodity code covering antihistamine medications and related pharmaceutical products procured by state and local health agencies, counties, and cooperative purchasing alliances. State and local governments buy brompheniramine and other pharmaceuticals primarily through two channels: direct county health purchases for community health initiatives and opioid-response programs, and through multistate cooperative purchasing agreements that aggregate demand across state agencies and participating jurisdictions to achieve volume pricing and standardized supply management. Recent solicitations show demand extending beyond brompheniramine to broader pharmaceutical categories, including naloxone, generic multi-source drugs, and over-the-counter products.

Seminole County, Florida, and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) represent the primary issuing bodies in recent activity. Seminole County issued IFB 60459723LAS in June 2026 seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to its Community Health Building in Sanford, Florida, with a response deadline of July 26, 2023. MMCAP, administered by the Minnesota Department of Administration's Office of State Procurement, posted an RFP (S1070000015802) in January 2026 for generic multi-source pharmaceuticals and OTC products to be distributed across participating state and local facilities in Minnesota and Oregon, with responses due March 26, 2026; awarded vendors will begin deliveries through authorized wholesalers (AmerisourceBergen, Cardinal Health, and Morris & Dickson) on July 1, 2026. The Texas Health and Human Services Commission issued an RFI (HHS0017013) in April 2026 to explore direct-to-manufacturer prescription fulfillment models, signaling potential longer-term state pharmaceutical procurement restructuring. Geographic activity centers in Florida, Minnesota, and Texas, with MMCAP's cooperative model extending participation across multiple states.